Table 2.
Results of subgroup analysis of pooled HRs of OS of HCC patients with high APRI
| Stratified analysis | No. of studies | No. of patients | Pooled HR (95% CI) | P-value | I2(%) | PQ |
|---|---|---|---|---|---|---|
| Analysis type | ||||||
| MVA | 10 | 4,009 | 1.41 (1.08–1.73) | <0.001 | 55.1 | 0.018 |
| UVA | 4 | 549 | 3.59 (2.32–4.87) | <0.001 | 5.2 | 0.367 |
| Cutoff value selection | ||||||
| ROC analysis | 9 | 3,806 | 1.46 (1.10–1.81) | <0.001 | 58.1 | 0.014 |
| Others | 5 | 752 | 3.08 (1.23–4.92) | 0.001 | 73.9 | 0.004 |
| Treatments | ||||||
| No surgery | 5 | 849 | 2.24 (1.14–3.33) | <0.001 | 72.5 | 0.006 |
| With surgery | 8 | 3,615 | 1.48 (1.07–1.90) | <0.001 | 63.3 | 0.008 |
| Mixed | 1 | 94 | 4.09 (1.59–10.50) | <0.001 | NA | NA |
Note: Relationship between APRI and RFS in HCC.
Abbreviations: APRI, aminotransferase-to-platelet ratio index; HCC, hepatocellular carcinoma; HR, hazard ratio; MVA, multivariate analysis; NA, not available; OS, overall survival; RFS, recurrence-free survival; ROC, receiver operating characteristic curve; UVA, univariate analysis.